SCHEMBL5041186

SCHEMBL5041186

CCO[C@](C)(C(=O)O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.49
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ALDH1A1 P00352 1/20 0.40
PTGS2 P35354 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041181 1.00 CYP2C9 (0.49) CYP2C9MAPTSMN1; SMN2L3MBTL1NPC1
SCHEMBL1670311 0.90 CYP2C19 (0.46) MAPTPPARGPPARALMNAALDH1A1
SCHEMBL6898466 0.90 CYP2C19 (0.46) MAPTPPARGPPARALMNAALDH1A1
SCHEMBL5037444 0.86 PIN1 (0.45) CYP2C9MAPTSMN1; SMN2L3MBTL1NPC1
SCHEMBL5037447 0.86 PIN1 (0.45) CYP2C9MAPTSMN1; SMN2L3MBTL1NPC1
SCHEMBL6055984 0.83 ESR1 (0.50) HPGDLMNAALDH1A1
SCHEMBL6061648 0.83 ESR1 (0.50) HPGDLMNAALDH1A1
SCHEMBL1678855 0.81 NPC1 (0.41) CYP2C9MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL4298978 0.77 LMNA (0.46) CYP2C9MAPTRAB9APPARGPPARA
SCHEMBL5383199 0.77 PPARA (0.59) SMN1; SMN2NPC1RAB9APPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 CYP2C9 325/4885MAPT 4423/4885SMN1; SMN2 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.